Loading...
Dermata Therapeutics, Inc.
DRMAW•NASDAQ
HealthcareBiotechnology
$0.02
$-0.01(-32.75%)
Dermata Therapeutics, Inc. (DRMAW) Company Profile & Overview
Explore Dermata Therapeutics, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Dermata Therapeutics, Inc. (DRMAW) Company Profile & Overview
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
SectorHealthcare
IndustryBiotechnology
CEOMr. Gerald T. Proehl
Contact Information
Company Facts
8 Employees
IPO DateAug 13, 2021
CountryUS
Actively Trading